SimBioSys
CEO at SimBioSys
The client had submitted a 510k for an AI/ML enabled software as a medical device. The FDA issued an additional information (AI) letter with a lot of tough questions surrounding the clinical performance study. The client was looking for a regulatory strategist to help them address FDA's concerns with the least amount of effort and shortest time possible.
The client secured FDA clearance soon after several rounds of correspondences with the FDA, all under our guidance. Even the client was pleasantly surprised by the clearance.
We began by reviewing all correspondences with the FDA, including the original submission, the FDA hold letter and the client's preliminary responses. We identified several software requirements that were extra risk control measures that were going above and beyond what is needed for the regulations. We successfully resolved FDA’s concerns and thereby sidestepped a lot of unnecessary verification and validation work. One finding in particular, would have caused the client to repeat their entire clinical performance study but we were able to find a pathway forward that did not require any additional work. The client recently received an FDA clearance letter, even when the client's team did not expect to receive.
Every great partnership starts with a conversation. Fill out the form below for a discovery call, and an Innolitics team member will contact you soon.